Extrovis AG ו- Dr. Reddy’s מכריזות על השקת התרופה הגנרית המורשית של CARAC (קרם פלואורואורציל), 0.5% בארה"ב.
Extrovis AG ו- Dr.
Reddy’s מכריזות על השקת התרופה הגנרית המורשית של
CARAC (קרם פלואורואורציל), 0.5% בארה"ב.
CARAC
(קרם פלואורואורציל), 0.5%
באר, שוויץ;
14 באוגוסט 2025, GLOBE
NEWSWIRE
Extrovis
AG, חברת תרופות גלובלית המתמקדת בחדשנות מונעת מחקר, ו- Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, יחד עם חברות
הבת שלה המכונות יחד "Dr. Reddy's"), הודיעו היום על השקת קרם
פלואורואורציל, 0.5%, מקבילה גנרית וטיפולית מורשית ל- Carac® (קרם פלואורואורציל) 0.5%, בשוק
האמריקאי, מאושר על ידי מנהל המזון
והתרופות האמריקני (USFDA).
Extrovis AG
and Dr. Reddy’s announce the launch of the authorized generic of CARAC
(fluorouracil cream), 0.5% in the U.S.
Baar, Switzerland; August 14, 2025, GLOBE NEWSWIRE
Extrovis AG, a global pharmaceutical company focused on
research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together
referred to as "Dr. Reddy's"), today announced the launch of
Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of
Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food
and Drug Administration (USFDA).
Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s
Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple
actinic or solar keratoses of the face and anterior scalp.
“This product generic launch marks a key milestone in our
commitment to increasing patient access and long-term value creation for the
U.S. healthcare system. Our partnership with Dr. Reddy’s helps ensure that
patients and healthcare providers in the United States have continued access to
a high-quality and cost-effective product,” said Hans R. Kamma Co-CEO and Chief
Strategy Officer of Extrovis AG.
“Dr. Reddy’s brings deep expertise in commercialization and
distribution within the U.S. market,” added Raghavendra Rao PV, Chief Financial
Officer of Extrovis AG. “This collaboration is aligned with our mission to
strengthen pharmaceutical supply chains and serve public health needs
responsibly.”
The partnership reinforces Extrovis’ strategy to extend the reach
of its therapeutics while advancing long-term affordability and sustainability
in healthcare.
Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30-gram
tube for topical use only. Please click here to see the full
prescribing information.
About Dr. Reddy’s
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company
headquartered in Hyderabad, India. Established in 1984, we are committed to
providing access to affordable and innovative medicines. Driven by our purpose
of ‘Good Health Can’t Wait’, we offer a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Our major markets include – USA,
India, Russia & CIS countries, China, Brazil and Europe. As a company with
a history of deep science that has led to several industry firsts, we continue
to plan ahead and invest in businesses of the future. As an early adopter of
sustainability and ESG actions, we released our first Sustainability Report in
2004. Our current ESG goals aim to set the bar high in environmental
stewardship; access and affordability for patients; diversity; and governance.
For more information, log on to: www.drreddys.com.
About Extrovis AG
Extrovis AG is a Switzerland-based global biopharmaceutical
company committed to developing and commercializing high-quality therapies for
unmet and under-addressed medical needs. With R&D and manufacturing
operations in the USA, Italy, Hungary, and India, Extrovis delivers innovative,
differentiated products across key therapeutic areas. Backed by strong R&D
capabilities, regulatory expertise, and a robust global quality framework, the
company advances its mission to improve patient outcomes and expand access to
essential health care products worldwide. For more information, log on
to: http://www.extrovis.com
תגובות
הוסף רשומת תגובה